FDA ended June with 5 new approvals.
*selinexor for r/r DLBCL
*pembrolizumab for cutaneous squamous cell carcinoma
*pembrolizumab for MSI-h/dMMR met. colorectal cancer
*avelumab maintenance for met. bladder cancer
*SC trastuzumab/pertuzumab/hyaluronidase
